Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin J Am Soc Nephrol
Main Authors: Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Nephrology 2019
Assuntos:
Feature
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
https://ncbi.nlm.nih.gov/pubmed/30635299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares